You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

hormone receptor positive (HR )

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

Recruiting
  • Locally Advanced or Unresectable Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Sacituzumab Govitecan-hziy
  • +3 more
  • Marietta, Georgia
  • +1 more
Apr 21, 2023

Metastatic Breast Cancer Trial in Dallas (DB-1303, Capecitabine, Paclitaxel)

Not yet recruiting
  • Metastatic Breast Cancer
  • Dallas, Texas
    Texas Oncology - Baylor Charles A. Sammons Cancer Center
Aug 25, 2023

Early-stage Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive Trial (Neratinib, Loperamide, Colesevelam)

Not yet recruiting
  • Early-stage Breast Cancer
  • +2 more
  • (no location specified)
Aug 5, 2022

Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Metastatic Breast Cancer
  • Hospitalet de Llobregat, Barcelona, Spain
  • +6 more
Jan 23, 2023

Advanced Hormone Receptor Positive (HR+) Breast Cancer Trial (everolimus)

No longer available
  • Advanced Hormone Receptor Positive (HR+) Breast Cancer
  • (no location specified)
Nov 26, 2021

Solid Tumor, Advanced Breast Cancer Trial in Milwaukee (Abemaciclib, Hydroxychloroquine 200 mg, Faslodex)

Withdrawn
  • Solid Tumor
  • Advanced Breast Cancer
  • Milwaukee, Wisconsin
    Froedtert Hospital and the Medical College of Wisconsin
Dec 21, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Among Patients Receiving Palbociclib Combinations for Hormone

Recruiting
  • Breast Neoplasms
  • Palbociclib plus an aromatase inhibitor
  • Palbociclib plus fulvestrant
  • Doha, Qatar
    Hamad Medical Corporation
Nov 18, 2021

A NIS of Alpelisib in Combination With Fulvestrant in

Not yet recruiting
  • Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
  • Alpelisib
  • Fulvestrant
  • (no location specified)
Aug 9, 2022

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer Trial in United States (Pembrolizumab, Sacituzumab

Recruiting
  • Invasive Breast Cancer
  • +3 more
  • Atlanta, Georgia
  • +7 more
Nov 14, 2022

Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer, Metastatic Epithelial Ovarian Cancer

Terminated
  • Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +2 more
Mar 16, 2022

HR Positive/HER2 Low Expression Metastatic Breast Cancer Trial in Guangzhou, Shantou, Qionghai (Disitamab vedotin, Endocrine

Recruiting
  • HR Positive/HER2 Low Expression Metastatic Breast Cancer
  • Disitamab vedotin
  • Endocrine therapy
  • Guangzhou, Guangdong, China
  • +2 more
Jun 19, 2023

Early-stage Breast Cancer, Hormone Receptor Positive Tumor Trial in Sydney (Letrozole, Letrozole and Prometrium, Tamoxifen and

Recruiting
  • Early-stage Breast Cancer
  • Hormone Receptor Positive Tumor
  • Sydney, New South Wales, Australia
    St Vincent's Hospital
Sep 23, 2021

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Breast Cancer Stage IV Trial in Nice, Villejuif (Alpelisib, Ribociclib)

    Not yet recruiting
    • Breast Cancer Stage IV
    • Nice, France
    • +1 more
    Nov 14, 2022

    HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

    Not yet recruiting
    • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
    • PERT-IJS plus trastuzumab, carboplatin and docetaxel
    • Perjeta plus trastuzumab, carboplatin and docetaxel
    • (no location specified)
    Sep 21, 2023

    Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Ocala, Florida
      Ocala Oncology Center PL DBA Florida Cancer Affiliates
    Jul 19, 2023

    Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

    Not yet recruiting
    • Breast Cancer Invasive
    • +3 more
    • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    Nov 17, 2023

    Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide,fulvestrant)

    Not yet recruiting
    • Hormone Receptor-positive Advanced Breast Cancer
    • (no location specified)
    Apr 12, 2023

    Brain Metastases, HR+ Metastatic Breast Cancer Trial in Tampa (Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy)

    Recruiting
    • Brain Metastases
    • HR+ Metastatic Breast Cancer
    • Stereotactic Radiosurgery (SRS)
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 1, 2022

    Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer Trial in United States (drug,

    Recruiting
    • Early-stage Breast Cancer
    • +6 more
    • Fullerton, California
    • +8 more
    Sep 19, 2022

    Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma Trial in Washington, Baltimore, Hackensack

    Active, not recruiting
    • Breast Cancer
    • +2 more
    • Washington, District of Columbia
    • +4 more
    Jan 31, 2023

    Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Boston

    Not yet recruiting
    • Breast Cancer
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Nov 3, 2022

    Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

    Active, not recruiting
    • Hormone-receptor-positive Breast Cancer
    • +2 more
    • No drug
    • Cambridge, Massachusetts
      ConcertAI database
    Sep 8, 2023